<?xml version='1.0' encoding='utf-8'?>
<document id="19049696"><sentence text="Pharmacokinetics of emtricitabine/tenofovir disoproxil fumarate and tacrolimus at steady state when administered alone or in combination."><entity charOffset="20-33" id="DDI-PubMed.19049696.s1.e0" text="emtricitabine" /><entity charOffset="34-63" id="DDI-PubMed.19049696.s1.e1" text="tenofovir disoproxil fumarate" /><entity charOffset="68-78" id="DDI-PubMed.19049696.s1.e2" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.19049696.s1.e0" e2="DDI-PubMed.19049696.s1.e0" /><pair ddi="false" e1="DDI-PubMed.19049696.s1.e0" e2="DDI-PubMed.19049696.s1.e1" /><pair ddi="false" e1="DDI-PubMed.19049696.s1.e0" e2="DDI-PubMed.19049696.s1.e2" /><pair ddi="false" e1="DDI-PubMed.19049696.s1.e1" e2="DDI-PubMed.19049696.s1.e1" /><pair ddi="false" e1="DDI-PubMed.19049696.s1.e1" e2="DDI-PubMed.19049696.s1.e2" /></sentence><sentence text="An open-label, randomized, 3-way crossover, drug-drug interaction study of the investigational anti-HBV combination agent, emtricitabine/tenofovir DF and the antirejection agent, tacrolimus was conducted in healthy volunteers to evaluate the potential for a pharmacokinetic interaction between these drugs"><entity charOffset="123-136" id="DDI-PubMed.19049696.s2.e0" text="emtricitabine" /><entity charOffset="137-146" id="DDI-PubMed.19049696.s2.e1" text="tenofovir" /><entity charOffset="179-189" id="DDI-PubMed.19049696.s2.e2" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.19049696.s2.e0" e2="DDI-PubMed.19049696.s2.e0" /><pair ddi="false" e1="DDI-PubMed.19049696.s2.e0" e2="DDI-PubMed.19049696.s2.e1" /><pair ddi="false" e1="DDI-PubMed.19049696.s2.e0" e2="DDI-PubMed.19049696.s2.e2" /><pair ddi="false" e1="DDI-PubMed.19049696.s2.e1" e2="DDI-PubMed.19049696.s2.e1" /><pair ddi="false" e1="DDI-PubMed.19049696.s2.e1" e2="DDI-PubMed.19049696.s2.e2" /></sentence><sentence text="" /><sentence text="Subjects received emtricitabine/tenofovir DF (200/300 mg q"><entity charOffset="18-31" id="DDI-PubMed.19049696.s4.e0" text="emtricitabine" /><entity charOffset="32-41" id="DDI-PubMed.19049696.s4.e1" text="tenofovir" /><pair ddi="false" e1="DDI-PubMed.19049696.s4.e0" e2="DDI-PubMed.19049696.s4.e0" /><pair ddi="false" e1="DDI-PubMed.19049696.s4.e0" e2="DDI-PubMed.19049696.s4.e1" /></sentence><sentence text="d" /><sentence text=") and tacrolimus (0"><entity charOffset="6-16" id="DDI-PubMed.19049696.s6.e0" text="tacrolimus" /></sentence><sentence text="1 mg/kg/day) alone or in combination for 7 days, with a 2-week washout between successive treatments" /><sentence text=" Drug concentrations were measured by LC/MS/MS and steady state pharmacokinetic parameters were calculated for each drug using noncompartmental methods" /><sentence text="" /><sentence text="The 90% confidence intervals (CIs) of the geometric least-squares mean ratio for AUCtau, Cmax and Ctau for each drug together vs" /><sentence text=" alone were within the predetermined no-effect boundaries of 80 - 125% (representing a maximum 20% effect), other than the upper limit of the 90% CI for tenofovir Cmax, which was just outside the 125% threshold" /><sentence text="" /><sentence text="It was concluded that there was no clinically relevant pharmacokinetic interaction between emtricitabine/tenofovir DF and tacrolimus when administered together"><entity charOffset="91-104" id="DDI-PubMed.19049696.s13.e0" text="emtricitabine" /><entity charOffset="105-114" id="DDI-PubMed.19049696.s13.e1" text="tenofovir" /><entity charOffset="122-132" id="DDI-PubMed.19049696.s13.e2" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.19049696.s13.e0" e2="DDI-PubMed.19049696.s13.e0" /><pair ddi="false" e1="DDI-PubMed.19049696.s13.e0" e2="DDI-PubMed.19049696.s13.e1" /><pair ddi="false" e1="DDI-PubMed.19049696.s13.e0" e2="DDI-PubMed.19049696.s13.e2" /><pair ddi="false" e1="DDI-PubMed.19049696.s13.e1" e2="DDI-PubMed.19049696.s13.e1" /><pair ddi="false" e1="DDI-PubMed.19049696.s13.e1" e2="DDI-PubMed.19049696.s13.e2" /></sentence><sentence text="" /></document>